Age-related changes in the innervation of the prostate gland: Implications for prostate cancer initiation and progression

Organogenesis

Volumn 9, Issue 3, 2013, Pages 206-215

  White, Carl W ^a   Xie, Jin Han ^a   Ventura, Sabatino ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Acetylcholine; Adrenoceptors; Autonomic nervous system; Muscarinic receptors; Noradrenaline; Parasympathetic nervous system; Sympathetic nervous system

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; ALPHA 1A ADRENERGIC RECEPTOR; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; CALCIUM; CELL PROTEIN; CYCLIC AMP; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; G PROTEIN COUPLED RECEPTOR KINASE; MUSCARINIC RECEPTOR; NEUROKININ A; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NITRIC OXIDE SYNTHASE; NORADRENALIN; PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C; PURINERGIC P2X1 RECEPTOR; RHO KINASE; STRESS ACTIVATED PROTEIN KINASE; TESTOSTERONE; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; ACETYLCHOLINE; ADRENERGIC RECEPTOR;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; AUTONOMIC INNERVATION; AUTONOMIC NERVOUS SYSTEM; BLADDER NECK STENOSIS; BLADDER OBSTRUCTION; CARCINOGENESIS; CELL PROLIFERATION; CHOLINERGIC SYSTEM; CONNECTIVE TISSUE; EJACULATORY DUCT; ENZYME ACTIVITY; GROWTH, DEVELOPMENT AND AGING; HUMAN; HYPOGASTRIC NERVE; LOWER URINARY TRACT SYMPTOM; MICTURITION; NOCTURIA; NONHUMAN; NORADRENERGIC NERVE; PARALYSIS; PELVIC NERVE; PROSTATE; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE FLUID; PROSTATE HYPERTROPHY; PROSTATE SECRETION; PROSTATE SIZE; PROTEIN PHOSPHORYLATION; REVIEW; SENSORY STIMULATION; SMOOTH MUSCLE; SMOOTH MUSCLE CONTRACTION; SPINAL CORD INJURY; SYMPATHECTOMY; URETHRA; URETHRA STRICTURE; ADRENOCEPTORS; ADULT; ANIMAL; DISEASE COURSE; INNERVATION; MALE; MIDDLE AGED; MOUSE; MUSCARINIC RECEPTORS; PHYSIOLOGY; PROSTATE TUMOR; YOUNG ADULT;

ACETYLCHOLINE; ADRENOCEPTORS; AUTONOMIC NERVOUS SYSTEM; MUSCARINIC RECEPTORS; NORADRENALINE; PARASYMPATHETIC NERVOUS SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

ACETYLCHOLINE; ADULT; ANIMALS; AUTONOMIC NERVOUS SYSTEM; DISEASE PROGRESSION; HUMANS; MALE; MICE; MIDDLE AGED; NOREPINEPHRINE; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ADRENERGIC; RECEPTORS, MUSCARINIC; YOUNG ADULT;

EID: 84883015997     PISSN: 15476278     EISSN: 15558592     Source Type: Journal    
DOI: 10.4161/org.24843     Document Type: Review

References (151)

1. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8:338-62; PMID:3308446; http://dx.doi.org/10.1210/edrv-8-3-338
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132:474-9; PMID:6206240
3. McNeal JE. Normal histology of the prostate. Am J Surg Pathol 1988; 12:619-33; PMID:2456702; http://dx.doi.org/10.1097/00000478-198808000-00003
4. Bruchovsky N, Wilson JD. The conversion of testosterone to 5-alpha- androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968; 243:2012-21; PMID:4384673
5. Fang S, Anderson KM, Liao S. Receptor proteins for androgens. On the role of specific proteins in selective retention of 17-beta-hydroxy-5-alpha- androstan-3-one by rat ventral prostate in vivo and in vitro. J Biol Chem 1969; 244:6584-95; PMID:5361546
6. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008; 73:233-44; PMID:18093629; http://dx.doi.org/10.1016/j.steroids.2007.10.013
7. Matzkin H, Soloway MS. Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues. Prostate 1992; 21:309-14; PMID:1281323; http://dx.doi.org/10.1002/pros.2990210407
8. Swyer GI. Post-natal growth changes in the human prostate. J Anat 1944; 78:130-45; PMID:17104953
9. Keast Jr. Visualization and immunohistochemical characterization of sympathetic and parasympathetic neurons in the male rat major pelvic ganglion. Neuroscience 1995; 66:655-62; PMID:7644029; http://dx.doi.org/10.1016/0306- 4522(94)00595-V
10. Keast Jr. Plasticity of pelvic autonomic ganglia and urogenital innervation. Int Rev Cytol 2006; 248:141-208; PMID:16487791; http://dx.doi.org/10.1016/S0074-7696(06)48003-7
11. Vaalasti A, Hervonen A. Autonomic innervation of the human prostate. Invest Urol 1980; 17:293-7; PMID:7351361
12. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975; 47:193-202; PMID:1148621; http://dx.doi.org/10.1111/j.1464-410X.1975.tb03947.x
13. Raz S, Zeigler M, Caine M. Pharmacological receptors in the prostate. Br J Urol 1973; 45:663-7; PMID:4775741; http://dx.doi.org/10.1111/j.1464-410X.1973. tb12237.x
14. Shapiro A, Mazouz B, Caine M. The alpha-adrenergic blocking effect of prazosin on the human prostate. Urol Res 1981; 9:17-20; PMID:6115493; http://dx.doi.org/10.1007/BF00256833
15. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, et al. International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev 1995; 47:267-70; PMID:7568329
16. Testa R, Guarneri L, Ibba M, Strada G, Poggesi E, Taddei C, et al. Characterization of alpha 1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man. Eur J Pharmacol 1993; 249:307-15; PMID:7904564; http://dx.doi.org/10.1016/0014-2999(93)90527-O
17. Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006; 147(Suppl 2):S88-119; PMID:16465187; http://dx.doi.org/10.1038/sj.bjp.0706619
18. Muramatsu I, Oshita M, Ohmura T, Kigoshi S, Akino H, Gobara M, et al. Pharmacological characterization of alpha 1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br J Urol 1994; 74:572-8; PMID:7530120; http://dx.doi.org/10.1111/j.1464-410X.1994.tb09186.x
19. Guh JH, Chueh SC, Ko FN, Teng CM. Characterization of alpha 1-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation. Br J Pharmacol 1995; 115:142-6; PMID:7647968; http://dx.doi.org/10.1111/j.1476-5381.1995.tb16331.x
20. Ohmura T, Sakamoto S, Hayashi H, Kigoshi S, Muramatsu I. Identification of alpha 1-adrenoceptor subtypes in the dog prostate. Urol Res 1993; 21:211-5; PMID:8102023; http://dx.doi.org/10.1007/BF00590038
21. Hiraoka Y, Ohmura T, Sakamoto S, Hayashi H, Muramatsu I. Identification of alpha 1-adrenoceptor subtypes in the rabbit prostate. J Auton Pharmacol 1995; 15:271-8; PMID:8576274; http://dx.doi.org/10.1111/j.1474-8673.1995.tb00310.x
22. Pennefather JN, Lau WA, Chin C, Story ME, Ventura S. alpha(1L)- adrenoceptors mediate noradrenaline-induced contractions of the guinea-pig prostate stroma. Eur J Pharmacol 1999; 384:25-30; PMID:10611415; http://dx.doi.org/10.1016/S0014-2999(99)00667-6
23. Hiraoka Y, Ohmura T, Oshita M, Watanabe Y, Morikawa K, Nagata O, et al. Binding and functional characterization of alpha1-adrenoceptor subtypes in the rat prostate. Eur J Pharmacol 1999; 366:119-26; PMID:10064160; http://dx.doi.org/10.1016/S0014-2999(98)00895-4
24. Gray KT, Ventura S. α1L-adrenoceptors mediate contractions of the isolated mouse prostate. Eur J Pharmacol 2006; 540:155-61; PMID:16716294; http://dx.doi.org/10.1016/j.ejphar.2006.04.016
25. Chapple CR, Aubry ML, James S, Greengrass PM, Burnstock G, Turner-Warwick RT, et al. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br J Urol 1989; 63:487-96; PMID:2471572; http://dx.doi.org/10.1111/j.1464-410X.1989.tb05942.x
26. Chapple CR, Burt RP, Andersson PO, Greengrass P, Wyllie M, Marshall I. Alpha 1-adrenoceptor subtypes in the human prostate. Br J Urol 1994; 74:585-9; PMID:7530122; http://dx.doi.org/10.1111/j.1464-410X.1994.tb09188.x
27. Lau WAK, Ventura S, Pennefather JN. Pharmacology of neurotransmission to the smooth muscle of the rat and the guinea-pig prostate glands. J Auton Pharmacol 1998; 18:349-56; PMID:9915599; http://dx.doi.org/10.1046/j.1365-2680. 1998.1860349.x
28. Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn 2007; 26(Suppl):948-54; PMID:17696159; http://dx.doi.org/10.1002/nau.20475
29. Strittmatter F, Walther S, Gratzke C, Göttinger J, Beckmann C, Roosen A, et al. Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3. Br J Pharmacol 2012; 166:1926-35; PMID:22364229; http://dx.doi.org/10.1111/j. 1476-5381.2012.01919.x
30. Walther S, Strittmatter F, Roosen A, Heinzer F, Rutz B, Stief CG, et al. Expression and alpha1-adrenoceptor regulation of caldesmon in human prostate smooth muscle. Urology 2012; 79:e5-12; PMID:22197205; http://dx.doi.org/10.1016/ j.urology.2011.10.053
31. Hedlund H, Andersson KE, Larsson B. Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. J Urol 1985; 134:1291-8; PMID:2414474
32. James S, Chapple CR, Phillips MI, Greengrass PM, Davey MJ, Turner-Warwick RT, et al. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. J Urol 1989; 142:438-44; PMID:2473223
33. Slater M, Barden JA, Murphy CR. Tyrosine kinase A, autonomic and transmitter receptors, but not innervation, are upregulated in the aging rat prostate. Acta Histochem 2000; 102:427-38; PMID:11145535; http://dx.doi.org/10. 1078/0065-1281-00565
34. Hieble JP, Caine M, Zalaznik E. In vitro characterization of the alpha-adrenoceptors in human prostate. Eur J Pharmacol 1985; 107:111-7; PMID:2579826; http://dx.doi.org/10.1016/0014-2999(85)90048-2
35. Poyet P, Gagne B, Lavoie M, Labrie F. Characteristics of the beta-adrenergic receptor in the rat ventral prostate using [125I]cyanopindolol. Mol Cell Endocrinol 1986; 48:59-67; PMID:2877909; http://dx.doi.org/10.1016/ 0303-7207(86)90166-8
36. Tsujii T, Azuma H, Yamaguchi T, Oshima H. A possible role of decreased relaxation mediated by beta-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia. Br J Pharmacol 1992; 107:803-7; PMID:1282075; http://dx.doi.org/10.1111/j.1476-5381.1992.tb14527.x
37. Goepel M, Wittmann A, Rübben H, Michel MC. Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate. Urol Res 1997; 25:199-206; PMID:9228673; http://dx.doi.org/10.1007/BF00941983
38. Haynes JM, Hill SJ. Beta-adrenoceptor-mediated inhibition of alpha 1-adrenoceptor-mediated and field stimulation-induced contractile responses in the prostate of the guinea pig. Br J Pharmacol 1997; 122:1067-74; PMID:9401771; http://dx.doi.org/10.1038/sj.bjp.0701494
39. Drescher P, Eckert RE, Madsen PO. Smooth muscle contractility in prostatic hyperplasia: role of cyclic adenosine monophosphate. Prostate 1994; 25:76-80; PMID:7518597; http://dx.doi.org/10.1002/pros.2990250204
40. Kalodimos PJ, Ventura S. Beta2-adrenoceptor-mediated inhibition of field stimulation induced contractile responses of the smooth muscle of the rat prostate gland. Eur J Pharmacol 2001; 431:81-9; PMID:11716846; http://dx.doi.org/10.1016/S0014-2999(01)01414-5
41. Normandin DE, Lodge NJ. Pharmacological characterization of the isolated canine prostate. J Urol 1996; 155:1758-61; PMID:8627879; http://dx.doi.org/10. 1016/S0022-5347(01)66193-7
42. Hennenberg M, Strittmatter F, Walther S, Hedlund P, Andersson KE, Stief CG, et al. α1-adrenoceptor activation induces phosphorylation of β2-adrenoceptors in human prostate tissue. BJU Int 2011; 108:922-8; PMID:21371241
43. McVary KT, Razzaq A, Lee C, Venegas MF, Rademaker A, McKenna KE. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994; 51:99-107; PMID:7918880; http://dx.doi.org/10.1095/biolreprod51.1. 99
44. Golomb E, Kruglikova A, Dvir D, Parnes N, Abramovici A. Induction of atypical prostatic hyperplasia in rats by sympathomimetic stimulation. Prostate 1998; 34:214-21; PMID:9492850; http://dx.doi.org/10.1002/(SICI)1097- 0045(19980215)34:3<214::AID-PROS9>3.0.CO;2-H
45. Kim J, Yanagihara Y, Kikugawa T, Ji M, Tanji N, Masayoshi Y, et al. A signaling network in phenylephrine-induced benign prostatic hyperplasia. Endocrinology 2009; 150:3576-83; PMID:19443575; http://dx.doi.org/10.1210/en. 2008-1782
46. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by α1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000; 60:4550-5; PMID:10969806
47. Roehrborn CG. Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 2006; 9:121-5; PMID:16304557; http://dx.doi.org/10.1038/sj.pcan. 4500849
48. Kanagawa K, Sugimura K, Kuratsukuri K, Ikemoto S, Kishimoto T, Nakatani T. Norepinephrine activates P44 and P42 MAPK in human prostate stromal and smooth muscle cells but not in epithelial cells. Prostate 2003; 56:313-8; PMID:12858360; http://dx.doi.org/10.1002/pros.10267
49. Dunzendorfer U, Jonas D, Weber W. The autonomic innervation of the human prostate. Histochemistry of acetylcholinesterase in the normal and pathologic states. Urol Res 1976; 4:29-31; PMID:59994; http://dx.doi.org/10.1007/BF00256133
50. Chapple CR, Crowe R, Gilpin SA, Gosling J, Burnstock G. The innervation of the human prostate gland - the changes associated with benign enlargement. J Urol 1991; 146:1637-44; PMID:1719253
51. Nadelhaft I. Cholinergic axons in the rat prostate and neurons in the pelvic ganglion. Brain Res 2003; 989:52-7; PMID:14519511; http://dx.doi.org/10. 1016/S0006-8993(03)03353-5
52. Caulfield MP, Birdsall NJM. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50:279-90; PMID:9647869
53. Smith ER. The stimulation of canine prostatic secretion by parasympathomimetic agents. J Pharmacol Exp Ther 1968; 164:312-6; PMID:5699092
54. Smith ER, Lebeaux MI. The mediation of the canine prostatic secretion provoked by hypogastric nerve stimulation. Invest Urol 1970; 7:313-8; PMID:4392480
55. Gup DI, Shapiro E, Baumann M, Lepor H. Contractile properties of human prostate adenomas and the development of infravesical obstruction. Prostate 1989; 15:105-14; PMID:2477832; http://dx.doi.org/10.1002/pros.2990150204
56. Fernández JLG, Rivera L, López PG, Recio P, Vela-Navarrete R, García-Sacristán A. Characterization of the muscarinic receptor mediating contraction of the dog prostate. J Auton Pharmacol 1998; 18:205-11; PMID:9788290; http://dx.doi.org/10.1046/j.1365-2680.1998.18486.x
57. Seki N, Suzuki H. Electrical and mechanical activity of rabbit prostate smooth muscles in response to nerve stimulation. J Physiol 1989; 419:651-63; PMID:2621646
58. Najbar-Kaszkiel AT, Di Iulio JL, Li CG, Rand MJ. Characterisation of excitatory and inhibitory transmitter systems in prostate glands of rats, guinea pigs, rabbits and pigs. Eur J Pharmacol 1997; 337:251-8; PMID:9430422; http://dx.doi.org/10.1016/S0014-2999(97)01270-3
59. Cohen ML, Drey K. Contractile responses in bladder body, bladder neck and prostate from rat, guinea pig and cat. J Pharmacol Exp Ther 1989; 248:1063-8; PMID:2539454
60. White CW, Short JL, Haynes JM, Evans RJ, Ventura S. The residual nonadrenergic contractile response to nerve stimulation of the mouse prostate is medi-ated by acetylcholine but not ATP in a comparison with the mouse vas deferens. J Pharmacol Exp Ther 2010; 335:489-96; PMID:20724483; http://dx.doi.org/10.1124/jpet.110.172130
61. White CW, Short JL, Haynes JM, Matsui M, Ventura S. Contractions of the mouse prostate elicited by acetylcholine are mediated by M(3) muscarinic receptors. J Pharmacol Exp Ther 2011; 339:870-7; PMID:21885618; http://dx.doi.org/10.1124/jpet.111.186841
62. Ventura S, Pennefather JN, Mitchelson F. Cholinergic innervation and function in the prostate gland. Pharmacol Ther 2002; 94:93-112; PMID:12191596; http://dx.doi.org/10.1016/S0163-7258(02)00174-2
63. Lau WAK, Pennefather JN, Mitchelson FJ. Cholinergic facilitation of neurotransmission to the smooth muscle of the guinea-pig prostate gland. Br J Pharmacol 2000; 130:1013-20; PMID:10882385; http://dx.doi.org/10.1038/sj.bjp. 0703409
64. Yazawa H, Saita Y, Iida E, Honma Y, Morita T, Honda K. Characterization of muscarinic cholinoceptor in primary culture of smooth muscle cells from human prostate. J Urol 1994; 152:2173-7; PMID:7966710
65. Yazawa H, Honda K. The M3-muscarinic cholinoceptor subtype in rat prostate and its down regulation by aging. Jpn J Pharmacol 1993; 61:319-24; PMID:8320877; http://dx.doi.org/10.1254/jjp.61.319
66. Saito M, Ohmasa F, Shomori K, Dimitriadis F, Ohiwa H, Shimizu S, et al. Rhos and Rho kinases in the rat prostate: their possible functional roles and distributions. Mol Cell Biochem 2011; 358:207-13; PMID:21720764; http://dx.doi.org/10.1007/s11010-011-0936-9
67. Ventura S, Dewalagama RK, Lau LCL. Adenosine 5′-triphosphate (ATP) is an excitatory cotransmitter with noradrenaline to the smooth muscle of the rat prostate gland. Br J Pharmacol 2003; 138:1277-84; PMID:12711628; http://dx.doi.org/10.1038/sj.bjp.0705167
68. Buljubasich R, Ventura S. Adenosine 5′-triphosphate and noradrenaline are excitatory cotransmitters to the fibromuscular stroma of the guinea pig prostate gland. Eur J Pharmacol 2004; 499:335-44; PMID:15381056; http://dx.doi.org/10.1016/j.ejphar.2004.07.080
69. Lee HY, Bardini M, Burnstock G. P2X receptor immunoreactivity in the male genital organs of the rat. Cell Tissue Res 2000; 300:321-30; PMID:10867827; http://dx.doi.org/10.1007/s004410000207
70. Gray KT, Ventura S. Evaluation of the mouse prostate as a suitable model for the study of human prostate function. J Pharmacol Toxicol Methods 2005; 51:41-50; PMID:15596113; http://dx.doi.org/10.1016/j.vascn.2004.07.001
71. Gray KT, Short JL, Ledent C, Ventura S. Targeted disruption of the A2A adenosine receptor reduces in-vitro prostate contractility in mature mice. Eur J Pharmacol 2008; 592:151-7; PMID:18655781; http://dx.doi.org/10.1016/j.ejphar. 2008.07.003
72. Preston A, Lau WA, Pennefather JN, Ventura S. Effects of adenine nucleosides and nucleotides on neuromuscular transmission to the prostatic stroma of the rat. Br J Pharmacol 2000; 131:1073-80; PMID:11082113; http://dx.doi.org/10.1038/sj.bjp.0703652
73. Preston A, Frydenberg M, Haynes JM. A1 and A2A adenosine receptor modulation of alpha 1-adrenoceptor-mediated contractility in human cultured prostatic stromal cells. Br J Pharmacol 2004; 141:302-10; PMID:14751869; http://dx.doi.org/10.1038/sj.bjp.0705535
74. Pennefather JN, Lau WAK, Mitchelson F, Ventura S. The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmaco-logical and histological studies. J Auton Pharmacol 2000; 20:193-206; PMID:11260358; http://dx.doi.org/10.1046/j.1365-2680.2000.00195.x
75. Wanigasekara Y, Kepper ME, Keast Jr. Immunohistochemical characterisation of pelvic autonomic ganglia in male mice. Cell Tissue Res 2003; 311:175-85; PMID:12596037
76. Davis B, Goepel M, Bein S, Chess-Williams R, Chapple CR, Michel MC. Lack of neuropeptide Y receptor detection in human bladder and prostate. BJU Int 2000; 85:918-24; PMID:10792177; http://dx.doi.org/10.1046/j.1464-410x.2000. 00573.x
77. Kopp J, Zhang X, Hökfelt T. Neuropeptide Y1 receptors in the rat genital tract. Regul Pept 1997; 70:149-60; PMID:9272627; http://dx.doi.org/10. 1016/S0167-0115(97)00028-1
78. Watts SW, Cohen ML. Effect of bombesin, bradykinin, substance P and CGRP in prostate, bladder body and neck. Peptides 1991; 12:1057-62; PMID:1724795; http://dx.doi.org/10.1016/0196-9781(91)90060-3
79. Ruscica M, Dozio E, Boghossian S, Bovo G, Martos Riaño V, Motta M, et al. Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. Endocrinology 2006; 147:1466-73; PMID:16339211; http://dx.doi.org/10.1210/en.2005-0925
80. Hedlund P, Ekström P, Larsson B, Alm P, Andersson KE. Heme oxygenase and NO-synthase in the human prostate-relation to adrenergic, cholinergic and peptide-containing nerves. J Auton Nerv Syst 1997; 63:115-26; PMID:9138243; http://dx.doi.org/10.1016/S0165-1838(96)00139-7
81. Juarranz MG, De Neef P, Robberecht P. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes. Prostate 1999; 41:1-6; PMID:10440869; http://dx.doi.org/10.1002/(SICI)1097-0045(19990915) 41:1<1::AID-PROS1>3.0.CO;2-A
82. Smith ER, Miller TB, Wilson MM, Appel MC. Effects of vasoactive intestinal peptide on canine prostatic contraction and secretion. Am J Physiol 1984; 247:R701-8; PMID:6388351
83. Crowe R, Chapple CR, Burnstock G. The human prostate gland: a histochemical and immunohistochemical study of neuropeptides, serotonin, dopamine beta-hydroxylase and acetylcholinesterase in autonomic nerves and ganglia. Br J Urol 1991; 68:53-61; PMID:1873692; http://dx.doi.org/10.1111/j. 1464-410X.1991.tb15257.x
84. Jen PYP, Dixon JS, Gearhart JP, Gosling JA. Nitric oxide synthase and tyrosine hydroxylase are colocalized in nerves supplying the postnatal human male genitourinary organs. J Urol 1996; 155:1117-21; PMID:8583576; http://dx.doi.org/10.1016/S0022-5347(01)66403-6
85. Walden PD, Marinese D, Srinivasan D, Tzoumaka E, Syyong HT, Ford AP, et al. Effect of neurokinins on canine prostate cell physiology. Prostate 2005; 63:358-68; PMID:15611996; http://dx.doi.org/10.1002/pros.20195
86. Abrahamsson PA, Dizeyi N, Alm P, di Sant'Agnese PA, Deftos LJ, Aumüller G. Calcitonin and calcitonin gene-related peptide in the human prostate gland. Prostate 2000; 44:181-6; PMID:10906733; http://dx.doi.org/10. 1002/1097-0045(20000801)44:3<181::AID-PROS1>3.0.CO;2-L
87. Ventura S, Lau WAK, Buljubasich S, Pennefather JN. Calcitonin gene-related peptide (CGRP) inhibits contractions of the prostatic stroma of the rat but not the guinea-pig. Regul Pept 2000; 91:63-73; PMID:10967202; http://dx.doi.org/10.1016/S0167-0115(00)00118-X
88. Arciszewski MB. Distribution of calcitonin gene-related peptide (CGRP), substance P (SP) and galanin (GAL) immunoreactive nerve fibers in the seminal vesicle and prostate of the male sheep. Ann Anat 2004; 186:83-7; PMID:14994916; http://dx.doi.org/10.1016/S0940-9602(04)80130-4
89. Crowe R, Milner P, Lincoln J, Burnstock G. Histochemical and biochemical investigation of adrenergic, cholinergic and peptidergic innervation of the rat ventral prostate 8 weeks after streptozotocin-induced diabetes. J Auton Nerv Syst 1987; 20:103-12; PMID:2444638; http://dx.doi.org/10.1016/0165-1838(87) 90107-X
90. Buljubasich S, Lau WA, Pennefather JN, Ventura S. An immunohistochemical and pharmacological study of tachykinins in the rat and guinea-pig prostate glands. Eur J Pharmacol 1999; 380:137-44; PMID:10513573; http://dx.doi.org/10. 1016/S0014-2999(99)00524-5
91. Palea S, Corsi M, Artibani W, Ostardo E, Pietra C. Pharmacological characterization of tachykinin NK2 receptors on isolated human urinary bladder, pros-tatic urethra and prostate. J Pharmacol Exp Ther 1996; 277:700-5; PMID:8627548
92. Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, et al. Characterization and localization of nitric oxide synthase in the human prostate. Urology 1995; 45:435-9; PMID:7533455; http://dx.doi.org/10.1016/S0090- 4295(99)80012-0
93. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology 1995; 45:440-6; PMID:7879335; http://dx.doi.org/10.1016/S0090-4295(99)80013-2
94. Aikawa K, Yokota T, Okamura H, Yamaguchi O. Endogenous nitric oxide-mediated relaxation and nitrinergic innervation in the rabbit prostate: the changes with aging. Prostate 2001; 48:40-6; PMID:11391685; http://dx.doi.org/10.1002/pros.1079
95. Uckert S, Küthe A, Jonas UDO, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166:2484-90; PMID:11696815; http://dx.doi.org/10. 1016/S0022-5347(05)65621-2
96. Chow PH, Dockery P, Cheung A. Innervation of accessory sex glands in the adult male golden hamster and quantitative changes of nerve densities with age. Andrologia 1997; 29:331-42; PMID:9430439; http://dx.doi.org/10.1111/j.1439-0272. 1997.tb00327.x
97. Moriyama N, Yamaguchi T, Takeuchi T, Sakamoto E, Ueki T, Tsujimoto G, et al. Semiquantitative evaluation of α1A-adrenoceptor subtype mRNA in human hypertrophied and non-hypertrophied prostates: Regional comparison. Life Sci 1998; 64:201-10; http://dx.doi.org/10.1016/S0024-3205(98)00552-9
98. Kojima Y, Sasaki S, Shinoura H, Hayashi Y, Tsujimoto G, Kohri K. Quantification of alpha1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. Prostate 2006; 66:761-7; PMID:16425183; http://dx.doi.org/10.1002/ pros.20399
99. Yono M, Foster HE Jr., Weiss RM, Latifpour J. Age related changes in the functional, biochemical and molecular properties of α1-adrenoceptors in the rat genitourinary tract. J Urol 2006; 176:1214-9; PMID:16890728; http://dx.doi.org/10.1016/j.juro.2006.04.038
100. Quinn R. Comparing rat's to human's age: how old is my rat in people years? Nutrition 2005; 21:775-7; PMID:15925305; http://dx.doi.org/10.1016/j.nut. 2005.04.002
101. Frisbie JH, Kumar S, Aguilera EJ, Yalla S. Prostate atrophy and spinal cord lesions. Spinal Cord 2006; 44:24-7; PMID:16010271; http://dx.doi.org/10. 1038/sj.sc.3101804
102. Justulin LA Jr., Delella FK, Felisbino SL. Doxazosin reduces cell proliferation and increases collagen fibers in rat prostatic lobes. Cell Tissue Res 2008; 332:171-83; PMID:18188599; http://dx.doi.org/10.1007/s00441-007-0559-3
103. Kojima Y, Sasaki S, Oda N, Koshimizu TA, Hayashi Y, Kiniwa M, et al. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia. Prostate 2009; 69:1521-8; PMID:19544328; http://dx.doi.org/10.1002/pros.21003
104. Mitropoulos D, Kyroudi-Voulgari A, Christelli E, Zervas A, Karayannacos P. Terazosin treatment suppresses basic fibroblast growth factor expression in the rat ventral prostate. Clin Invest Med 2009; 32:E1-7; PMID:19178873
105. Lepor H, Berry SJ. Decreased prostatic secretory function in canine benign prostatic hyperplasia is not due to decreased levels of muscarinic cholinergic receptors. J Urol 1984; 131:803-5; PMID:6200613
106. Kondo S, Tashima Y, Morita T. Adrenergic and cholinergic muscarinic receptors in the prostate of young and old rabbits. Urol Int 1992; 49:201-5; PMID:1335627; http://dx.doi.org/10.1159/000282426
107. Saito M, Kazuyama E, Shimizu S, Dimitriadis F, Kinoshita Y, Masuda E, et al. Muscarinic receptors and their mRNAs in type 2 Goto-Kakizaki diabetic rat prostate. Prostate 2010; 70:1533-9; PMID:20687226; http://dx.doi.org/10.1002/ pros.21188
108. Chen C, Ishikawa Y, Amano I, Eguchi T, Ishida H. Age-dependent changes in response of rat prostatic tissues to isoproterenol and forskolin: changes with sexual maturation in function of G proteins. Mech Ageing Dev 1995; 81:1-13; PMID:7475348; http://dx.doi.org/10.1016/0047-6374(94)01577-9
109. Dey A, Lang RJ, Exintaris B. Nitric oxide signaling pathways involved in the inhibition of spontaneous activity in the guinea pig prostate. J Urol 2012; 187:2254-60; PMID:22503041; http://dx.doi.org/10.1016/j.juro.2012.01.072
110. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al.; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:167-78; PMID:11857671; http://dx.doi.org/10.1002/nau.10052
111. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44:637-49; PMID:14644114; http://dx.doi.org/10.1016/j.eururo.2003.08.015
112. Barry MJ. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology 2001; 58(Suppl 1):25-32, discussion 32; PMID:11750246; http://dx.doi.org/10.1016/S0090-4295(01)01300-0
113. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49:651-8; PMID:16530611; http://dx.doi.org/10.1016/j.eururo.2006.02.018
114. Kirby RS, Kirby M, Fitzpatrick JM. Benign prostatic hyperplasia: counting the cost of its management. BJU Int 2010; 105:901-2; PMID:20356323; http://dx.doi.org/10.1111/j.1464-410X.2010.09274.x
115. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978; 15:340-5; PMID:75197
116. Bartsch G, Müller HR, Oberholzer M, Rohr HP. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979; 122:487-91; PMID:90177
117. Dmochowski RR. Bladder outlet obstruction: etiology and evaluation. Rev Urol 2005; 7(Suppl 6):S3-13; PMID:16986027
118. Lepor H. Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol 2005; 7(Suppl 7):S3-11; PMID:16986059
119. Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 2008; 54:419-26; PMID:18325657; http://dx.doi.org/10.1016/j.eururo.2008.02.017
120. Yamada S, Ashizawa N, Ushijima H, Nakayama K, Hayashi E, Honda K. Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy. J Pharmacol Exp Ther 1987; 242:326-30; PMID:2441028
121. Haynes JM, Ventura S. Current models of human prostate contractility. Clin Exp Pharmacol Physiol 2005; 32:797-804; PMID:16173939; http://dx.doi.org/ 10.1111/j.1440-1681.2005.04268.x
122. Ventura S, Oliver Vl, White CW, Xie JH, Haynes JM, Exintaris B. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br J Pharmacol 2011; 163:891-907; PMID:21410684; http://dx.doi.org/10.1111/j.1476- 5381.2011.01332.x
123. Song W, Yuan M, Zhao S. Variation of M3 muscarinic receptor expression in different prostate tissues and its significance. Saudi Med J 2009; 30:1010-6; PMID:19668880
124. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005; 5:21-8; PMID:15630412; http://dx.doi.org/10.1038/nrc1528
125. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-20; PMID:15470214; http://dx.doi.org/10.1056/NEJMoa041318
126. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al.; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-12; PMID:15470213; http://dx.doi.org/10.1056/NEJMoa040720
127. Kyprianou N, Litvak JP, Borkowski A, Alexander R, Jacobs SC. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998; 159:1810-5; PMID:9598465; http://dx.doi.org/10.1016/S0022-5347(01)63162-8
128. Giardinà D, Martarelli D, Sagratini G, Angeli P, Ballinari D, Gulini U, et al. Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity. J Med Chem 2009; 52:4951-4; PMID:19719240; http://dx.doi.org/10.1021/jm8016046
129. Liu CM, Lo YC, Tai MH, Wu BN, Wu WJ, Chou YH, et al. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin pro-vide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts. Prostate 2009; 69:610-23; PMID:19143029; http://dx.doi.org/10.1002/pros.20919
130. Tahmatzopoulos A, Rowland RG, Kyprianou N. The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother 2004; 5:1279-85; PMID:15163273; http://dx.doi.org/10.1517/14656566.5.6.1279
131. Haynes JM, Frydenberg M, Majewski H. Testosterone- and phorbol ester-stimulated proliferation in human cultured prostatic stromal cells. Cell Signal 2001; 13:703-9; PMID:11602180; http://dx.doi.org/10.1016/S0898-6568(01) 00205-4
132. Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001; 61:2866-9; PMID:11306460
133. Palm D, Lang K, Niggemann B, Drell TL 4th, Masur K, Zaenker KS, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006; 118:2744-9; PMID:16381019; http://dx.doi.org/10.1002/ijc.21723
134. Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A, et al. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest 2013; 123:874-86; PMID:23348742
135. Rayford W, Noble MJ, Austenfeld MA, Weigel J, Mebust WK, Shah GV. Muscarinic cholinergic receptors promote growth of human prostate cancer cells. Prostate 1997; 30:160-6; PMID:9122040; http://dx.doi.org/10.1002/(SICI)1097- 0045(19970215)30:3<160::AID-PROS3>3.0.CO;2-Q
136. Batra S, Christensson PI, Hartley-Asp B. Characterization of muscarinic cholinergic receptors in membrane preparations from rat prostatic adeno-carcinoma. Prostate 1990; 17:261-8; PMID:2251221; http://dx.doi.org/10. 1002/pros.2990170402
137. Rao J, Yang J, Liu Z, Wang L, Yin Z, Liu L, et al. Hypothetic association between greater sympathetic activity and prostate cancer. Med Hypotheses 2008; 71:442-3; PMID:18472228; http://dx.doi.org/10.1016/j.mehy.2008.03.039
138. Esler M, Rumantir M, Kaye D, Lambert G. The sympathetic neurobiology of essential hypertension: disparate influences of obesity, stress, and noradrenaline transporter dysfunction? Am J Hypertens 2001; 14:139S-46S; PMID:11411749; http://dx.doi.org/10.1016/S0895-7061(01)02081-7
139. Moyad MA. Is obesity a risk factor for prostate cancer, and does it even matter? A hypothesis and different perspective. Urology 2002; 59(Suppl 1):41-50; PMID:11937435; http://dx.doi.org/10.1016/S0090-4295(01)01175-X
140. Gann PH, Daviglus ML, Dyer AR, Stamler J. Heart rate and prostate cancer mortality: results of a prospective analysis. Cancer Epidemiol Biomarkers Prev 1995; 4:611-6; PMID:8547827
141. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 2001; 11:534-42; PMID:11709272; http://dx.doi.org/10.1016/ S1047-2797(01)00246-0
142. Mortensen PB. Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients. Acta Psychiatr Scand 1992; 85:390-3; PMID:1351334; http://dx.doi.org/10.1111/j.1600-0447.1992.tb10325.x
143. Rosenberg DJ, Neugut AI, Ahsan H, Shea S. Diabetes mellitus and the risk of prostate cancer. Cancer Invest 2002; 20:157-65; PMID:11901534; http://dx.doi.org/10.1081/CNV-120001141
144. Scott PA Sr., Perkash I, Mode D, Wolfe VA, Terris MK. Prostate cancer diagnosed in spinal cord-injured patients is more commonly advanced stage than in able-bodied patients. Urology 2004; 63:509-12; PMID:15028447; http://dx.doi.org/10.1016/j.urology.2003.10.022
145. Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004; 15:535-41; PMID:15280632; http://dx.doi.org/10.1023/B:CACO.0000036152.58271.5e
146. Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, et al. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 2007; 178:2176-80; PMID:17870114; http://dx.doi.org/10.1016/j.juro.2007.06.043
147. Murtola TJ, Tammela TL, Määttänen L, Ala-Opas M, Stenman UH, Auvinen A. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer 2009; 101:843-8; PMID:19654575; http://dx.doi.org/10.1038/sj.bjc.6605188
148. Ramsköld D, Luo S, Wang YC, Li R, Deng Q, Faridani OR, et al. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol 2012; 30:777-82; PMID:22820318; http://dx.doi.org/ 10.1038/nbt.2282
149. Thebault S, Roudbaraki M, Sydorenko V, Shuba Y, Lemonnier L, Slomianny C, et al. Alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells. J Clin Invest 2003; 111:1691-701; PMID:12782672
150. Katsogiannou M, El Boustany C, Gackiere F, Delcourt P, Athias A, Mariot P, et al. Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cells. PLoS One 2009; 4:e7068; PMID:19763272; http://dx.doi.org/10.1371/journal.pone.0007068
151. Jensen BC, Swigart PM, Simpson PC. Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch Pharmacol 2009; 379:409-12; PMID:18989658; http://dx.doi.org/10.1007/s00210-008- 0368-6